Lorem ipsum dolor sit amet consectetur adipiscing elit
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam urna tempor. Pulvinar vivamus fringilla lacus nec metus bibendum egestas. Iaculis massa nisl malesuada lacinia integer nunc posuere. Ut hendrerit semper vel class aptent taciti sociosqu. Ad litora torquent per conubia nostra inceptos himenaeos.
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam urna tempor. Pulvinar vivamus fringilla lacus nec metus bibendum egestas. Iaculis massa nisl malesuada lacinia integer nunc posuere. Ut hendrerit semper vel class aptent taciti sociosqu. Ad litora torquent per conubia nostra inceptos himenaeos.
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam urna tempor. Pulvinar vivamus fringilla lacus nec metus bibendum egestas. Iaculis massa nisl malesuada lacinia integer nunc posuere. Ut hendrerit semper vel class aptent taciti sociosqu. Ad litora torquent per conubia nostra inceptos himenaeos.
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam urna tempor. Pulvinar vivamus fringilla lacus nec metus bibendum egestas. Iaculis massa nisl malesuada lacinia integer nunc posuere. Ut hendrerit semper vel class aptent taciti sociosqu. Ad litora torquent per conubia nostra inceptos himenaeos.
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam urna tempor. Pulvinar vivamus fringilla lacus nec metus bibendum egestas. Iaculis massa nisl malesuada lacinia integer nunc posuere. Ut hendrerit semper vel class aptent taciti sociosqu. Ad litora torquent per conubia nostra inceptos himenaeos.
Lorem ipsum dolor sit amet consectetur adipiscing elit. Quisque faucibus ex sapien vitae pellentesque sem placerat. In id cursus mi pretium tellus duis convallis. Tempus leo eu aenean sed diam urna tempor. Pulvinar vivamus fringilla lacus nec metus bibendum egestas. Iaculis massa nisl malesuada lacinia integer nunc posuere. Ut hendrerit semper vel class aptent taciti sociosqu. Ad litora torquent per conubia nostra inceptos himenaeos.
Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...
Using Decipher in the SPPORT Study: Determining Response to Randomized Post-Prostatectomy Salvage RT
Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
Dr. Ciuro discusses key factors to consider when choosing between doublet and triplet therapy for mHSPC.
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Focus on Muscle-Invasive, Advanced Bladder Cancer
The panel weighs the impact of long-term survival data from the EV-302 trial, with significant improvements in OS.
The panel debates patient selection, alternative regimens, and the balance between escalation and de-escalation strategies.
The panel covers 2L treatment options for mUC post-EV/pembro, with emphasis on platinum-based chemo and targeted therapy.
The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.
The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.
The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.
Focus on Advanced RCC
The panel weighs the evolving role of biomarkers, particularly the promising blood-based biomarker KIM-1.
The panel considers the limitations of ctDNA from low tumor shedding but expresses optimism for detection technology.
The panel weighs long-term treatment-free survival with nivo/ipi against the need for disease control with IO-TKI combos.
The panel explains how the approval of subcutaneous nivo offers advantages in patient convenience and healthcare efficiency.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
Focus on mHSPC
The panel explores the the role of imaging, genomics, and patient factors in the management of mHSPC.
The panel goes in-depth on the use of testing and SBRT as metastasis-directed therapy in newly diagnosed prostate cancer.
The panel focuses on decision-making between AR antagonists and abiraterone, weighing factors such as reimbursement.
The panel zooms in on the use of radium, enzalutamide, and other therapeutic agents, touching on patient preference trials.
The panel highlights the limitations of conventional imaging in detecting disease progression at undetectable PSA levels.
Focus on Adjuvant RCC
Part one of the discussion covers adjuvant therapy in kidney cancer, patient selection, and balancing risks and benefits.
In part 2, the panelists discuss adjuvant therapy for RCC, including biomarkers and optimizing treatment for better outcomes.
The panel discusses considerations for triplet therapy in RCC, new trial data, and biomarker-driven treatment strategies.
The panel explores the evolving role of cytoreductive nephrectomy in RCC and how biomarkers shape treatment decisions.
Sequencing, novel therapies, and treatment combinations for refractory RCC are examined in part 5 of this discussion.
Focus on Advanced, Metastatic Prostate Cancer
Experts discuss advances in biomarker testing, treatment intensification, and the impact of TALAPRO-2 in prostate cancer care
The panelists examine biomarker adoption challenges and the impact of PSMA PET on staging and treatment decisions.
The panel covers metastasis-directed therapy and trials including SWOG 1802 in oligometastatic prostate cancer.
The experts discuss treatment selection in mHSPC and share insights from STOPCAP and ARANOTE on ARSI use in older patients.
The panel discusses data from PEACE-3 and maintaining ARSI therapy with emerging combination treatments.
The panel highlights key ASCO GU 2025 data, including TALAPRO-2, PSMA PET, the PORTOS score, and emerging therapies like EZH2
Focus on BCG-Unresponsive NMIBC
Part one of this roundtable highlights current practices, emerging therapies, and the future landscape of NMIBC care.
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
The second segment of this roundtable focuses on the evolving landscape of treatments for BCG-unresponsive bladder cancer.
The panelists share their perspectives on SunRISe-1 and the evolving role of TAR-200 in treating BCG-unresponsive UC.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
Focus on Progression From mHSPC to mCRPC
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
Focus on Clinical Trials in NMIBC
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
Focus on TiNivo-2 in RCC
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
Focus on Categorizing, Risk Stratifying Prostate Cancer
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
Focus on mHSPC
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Focus on Evolving Imaging in Prostate Cancer
The first part of this roundtable focuses on the impact of recent research on clinical practice.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Focus on MIBC
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
The third segment of this roundtable series focuses on the latest developments in bladder cancer treatments.
In part four of this roundtable, the use of immunotherapy in the adjuvant setting for bladder cancer is discussed.
The fifth segment of this roundtable series focuses on the use of circulating tumor DNA (ctDNA) in managing bladder cancer.
The final segment of this roundtable series addresses the future of immunotherapy combinations.
Focus on New Frontiers in RCC Treatment
An expert panel debates the latest strategies for optimizing first-line treatment for advanced renal cell carcinoma.
The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA.
The third segment of this roundtable focuses on key treatment endpoints when deciding between IO-IO and IO-TKI regimens.
The fourth segment of this roundtable series focuses on the potential benefits of subcutaneous nivolumab versus IV nivolumab.
In the fifth segment of this roundtable, the panelists discuss the challenges and barriers of ipi-nivo therapy.
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
Focus on RLT
The panel discusses the role of PSMA imaging in prostate cancer, theranostics, and radioligand therapy.
An expert panel discusses the evolving landscape of radioligand therapy for prostate cancer.
The third part of this roundtable explores imaging interpretation and toxicity management.
The fourth part of this roundtable delves into the VISION and PSMAfore studies and their implications.
The fifth segment of the RLT roundtable explores recent clinical trials, including the VISION study.
The challenges of patient management and access to care are explored in the sixth part of our RLT roundtable discussion.
Focus on Neoadjuvant, Adjuvant nccRCC
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
Focus on PSMA Imaging, RLTs
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
Focus on NMIBC, MIBC
In part 1, the panelists examine the evolving treatment landscape of MIBC and NMIBC, including discussion on new trials.
In the second part of this roundtable, new trials including VOLGA and EV-304 are analyzed.
In part 3 of this roundtable, the NIAGARA trial is discussed, along with cisplatin regimens and the potential of durvalumab.
In the fourth part of this roundtable series, the panelists discuss recent updates on bladder-sparing treatments.
In part five of this roundtable, the panelists explore the use of ctDNA in the TOMBOLA and IMvigor011 trials.
In the final part of this roundtable, Drs. Koshkin and Grivas discuss the use of EV/pembro and which patients are eligible.
Focus on NMIBC Treatment Management
The first part of six roundtable sessions on treatment advancements in NMIBC.
The second part of this roundtable series on NMIBC explores the relevant and current clinical trials.
Panelists discuss the data pipeline from clinical trials to the community setting in the third part of this series on NMIBC.
The fourth part of this series focuses on the past and future landscape of clinical trials and logistic considerations.
The panelists compare what they describe as apples and oranges.
The panelists consider patient expectations, considerations, and how they handle setting those expectations.
Focus on HSPC, CRPC
In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options.
In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients.
In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs.
In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities.
In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
Focus on Metastatic Prostate Cancer
Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing.
Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial.
At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial.
The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results.
Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial.
Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer.
Focus on Non-Clear Cell RCC
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
Focus on Advanced, Metastatic RCC Sequencing, Management
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
Focus on UTUC
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
Focus on RCC Treatment, Management
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their excitement for the road ahead in kidney cancer.
Focus on Advanced Kidney Cancer
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
Focus on Metastatic Urothelial Carcinoma
The panel discussed how enfortumab vedotin and pembrolizumab figures to change the bladder cancer treatment landscape.
The panel considered treatment options for patients with mUC who are not eligible for EV/pembrolizumab.
The panel weighed in on treatment selection after patient progression on EV/pembrolizumab.
The panel transitioned to the AMBASSADOR trial findings and other adjuvant treatment considerations for urothelial carcinoma.
The panel highlighted new data released on SG, including real-world findings and relevant results from the UNITE trial.
The panel considered the latest available data pertaining to EV, atezolizumab, erdafitinib, and other therapy options.
The panel concludes with their forward-thinking thoughts on the impending direction of urothelial carcinoma treatment.
Focus on Clear Cell and Non-Clear Cell RCC
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Dr. McDermott advocates for immune therapy in frontline RCC care.
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
The panel shifts to focus on the current state of non-clear cell kidney cancer.
The panel discussed important takeaways from RCC studies presented at ASCO GU.
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Testing
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.